]. In addition to one of the administration properties, CAR-T cells remain in the body for a month to a year, which can cause “on-target/off-tumor” toxicity. The comparative study by Rotolo et al. showed that CD1d-restricted engineered CD19-CAR-NKT cells acted more effectively than CD19-CAR-T cells against CD1d-expressing lymphomas.
The solid tumor complex structure makes a strong barrier to different treatments, but the results for CAR-NKT cells are hopeful. Unfortunately, the comparison between CAR-T- and CAR-NKT-cells has not been made in solid tumors, but the comparison in other cancer types showed better results of CAR-NKT cell therapies. In comparison with CAR19-T cells, CAR19-NKT cells, exhibited more effective tumor suppression with a higher penetration rate into the CNS and a greater survival rate [].
Car Car Latest News, Car Car Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Source: Glasgow_Times - 🏆 76. / 59 Read more »
Source: autosport - 🏆 90. / 53 Read more »
Source: Motorsport - 🏆 11. / 86 Read more »
Source: thelincolnite - 🏆 121. / 51 Read more »